TGFβ1, back to the future: Revisiting its role as a transforming growth factor

Cancer Biology and Therapy

Volumn 3, Issue 3, 2004, Pages 276-283

  Glick, Adam B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

EMT; Metastasis; Mouse models; Neovascularization; TGF 1; Tumor progression

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; CANCER; CANCER GROWTH; EPIGENETICS; GENE MUTATION; GENE OVEREXPRESSION; GENE SWITCHING; HUMAN; IMMUNE DEFICIENCY; METASTASIS; METASTASIS INHIBITION; MICROENVIRONMENT; MOLECULAR DYNAMICS; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE; ANIMAL; CANCER INVASION; CARCINOMA; DISEASE COURSE; DISEASE MODEL; GENETICS; IMMUNOLOGICAL TOLERANCE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PROGNOSIS;

ANIMALS; CARCINOMA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNE TOLERANCE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 15244340251     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.3.849     Document Type: Review

References (92)

1. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst 2000; 92:1388-402.
2. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998; 67:753-91.
3. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003; 425:577-84.
4. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000; 342:1350-8.
5. Liu X., LeeJ, Cooley M, Bhogte E, Hartley S, Glick A. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res 2003; 63:7760-8.
6. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res 1992; 52:6949-52.
7. 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995; 4:549-54.
8. Picon A, Gold LI, Wang J, Cohen A, Friedman E. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor β1. Cancer Epidemiol Biomarkers Prev 1998; 7:497-504.
9. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-β 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993; 143:381-9.
10. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-β1 in patients with colorectal carcinoma: Its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999; 85:554-61.
11. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, et al. High levels of transforming growth factor β 1 in patients with colorectal cancer: Association with disease progression. Gastroenterology 1996; 110:375-82.
12. Takanami I, Tanaka F, Hashizume T, Kodaira S. Roles of the transforming growth factor β 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: Results of an immunohistochemical study. J Surg Oncol 1997; 64:262-7.
13. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. An elevated serum level of transforming growth factor-β 1 (TGF-β 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 2000; 20:4489-93.
14. Sheen-Chen SM, Chen HS, Sheen CW, Eng HL, Chen WJ. Serum levels of transforming growth factor β1 in patients with breast cancer. Arch Surg 2001; 136:937-40.
15. Welch D, Fabra A, Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990; 87:7678-82.
16. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, et al. Excessive production of transforming growth-factor β 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1992; 1137:189-96.
17. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA. Transforming growth factor β 1 can induce estrogen- independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 1993; 4:193-201.
18. Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1. J Cell Biol 1992; 118:715-26.
19. Glick AB, Lee MM, Darwiche N, Kulkarni AB, Karlsson S, Yuspa SH. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 1994; 8:2429-40.
20. Amendt C, Schirmacher P, Weber H, Blessing M. Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 1998; 17:25-34.
21. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, et al. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996; 86:531-42.
22. Weeks BH, He W, Olson KL, Wang XJ. Inducible expression of transforming growth factor β1 in papillomas causes rapid metastasis. Cancer Res 2001; 61:7435-43.
23. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, et al. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor β1. Mol Cell Biol 2003; 23:8691-703.
24. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003; 100:8430-5.
25. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, et al. Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. Oncogene 1996; 12:2641-9.
26. Oft M, Heider KH, Beug H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998; 8:1243-52.
27. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, et al. TGF-β switches from I tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003; 112:1116-24.
28. Tian F, DaCosta Byfield S, Parks WT, Yoo S, Felici A, Tang B, et al. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 2003; 63:8284-92.
29. Tu WH, Thomas TZ, Masumori N, Bhowmick NA, Gorska AE, Skyr Y, et al. The loss of TGF-β signaling promotes prostate cancer metastasis. Neoplasia 2003; 5:267-77.
30. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002; 109:1551-9.
31. Yang YA, Dukkanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002; 109:1607-15.
32. Bogenrieder T, Herlyn M. Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene 2003; 22:6524-36.
33. Santibanez JF, Frontelo P, Iglesias M, Martinez J, Quintanilla M. Urokinase expression and binding activity associated with the transforming growth factor β1-induced migratory and invasive phenotype of mouse epidermal keratinocytes. J Cell Biochem 1999; 74:61-73.
34. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, et al. Transforming growth factor-β1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 1998; 75:721-30.
35. Dong-Le Bourhis X, Lambrecht V, Boilly B. Transforming growth factor β 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells. Br J Cancer 1998; 77:396-03.
36. Sappino AP, Schurch W, Gabbiani G. Differentiation repertoire of fibroblastic cells: Expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 1990; 63:144-61.
37. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995; 95:859-73.
38. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83:4167-71.
39. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Skappell S, et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303:848-51.
40. Thiery JP, Chopin D. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 1999; 18:31-42.
41. Lewis JE, Olsen KD, Sebo TJ. Spindle cell carcinoma of the larynx: Review of 26 cases including DNA content and immunohistochemistry. Hum Pathol 1997; 28:664-73.
42. Iyer PV, Leong AS. Poorly differentiated squamous cell carcinomas of the skin can express vimentin. J Cutan Pathol 1992; 19:34-9.
43. Fuchs IB, Lichtenegger W, Buehler H, Henrich W, Stein H, Kleine-Tebbe A, et al. The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 2002; 22:3415-9.
44. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors. J Cell Biol 1994; 127:2021-36.
45. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996; 10:2462-77.
46. Portella G, Cumming SA, Liddell J, Cui W, Ireland H, Akhurst RJ, et al. Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: Implications for tumor invasion. Cell Growth Differ 1998; 9:393-404.
47. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, et al. Transforming growth factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001; 61:4222-8.
48. Masszi A, Di Ciano C, Sirokmany G, Arthur WT, Rotstein OD, Wang J, et al. Central role for Rho in TGF-β1-induced α-smooth muscle actin expression during epithelial-mesenchymal transition. Am J Physiol Renal Physiol 2003; 284:F911-24.
49. Kitagawa K, Murata A, Matsuura N, Tohya K, Takaichi S, Monden M, et al. Epithelial-mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-β1. Int J Cancer 1996; 66:91-7.
50. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112:1486-94.
51. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000; 275:36803-10.
52. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001; 12:27-36.
53. Edlund S, Landstrom M, Heldin CH, Aspenstrom P. Transforming Growth Factor-β-induced Mobilization of Actin Cytoskeleton Requires Signaling by Small GTPases Cdc42 and RhoA. Mol Biol Cell 2002; 13:902-14.
54. Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002; 21:3241-6.
55. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002; 62:1013-8.
56. Peinado H, Quintanilla M, Cano A. Transforming growth factor β-1 induces snail transcription factor in epithelial cell lines: Mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003; 278:21113-23.
57. Merwin JR, Anderson JM, Kocher O, Van Itallie CM, Madri JA. Transforming growth factor β 1 modulates extracellular matrix organization and cell-cell junctional complex formation during in vitro angiogenesis. J Cell Physiol 1990; 142:117-28.
58. Yang EY, Moses HL. Transforming growth factor β 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990; 111:731-41.
59. Akhurst RJ, Derynck R. TGF-β signaling in cancer - a double-edged sword. Trends Cell Biol 2001; 11:S44-51.
60. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37:19-29.
61. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001; 91:964-71.
62. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. The expression of transforming growth factor-β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999; 86:1455-62.
63. Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. Role of interleukin 10 and transforming growth factor β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 1999; 5:711-20.
64. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. Inhibition of transforming growth factor-β activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002; 62:6021-5.
65. Go C, Li P, Wang XJ. Blocking transforming growth factor β signaling in transgenic epidermis accelerates chemical carcinogenesis: A mechanism associated with increased angiogenesis. Cancer Res 1999; 59:2801-8.
66. Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 2000; 97:9624-9.
67. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmond HP, Bouchier-Hayes DJ. TGF β-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol 1997; 4:621-7.
68. Benckert C, Jonas S, Cramer T, Von Marschall Z, Schafer G, Peters M, et al. Transforming growth factor β 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003; 63:1083-92.
69. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immunol 1998; 16:137-61.
70. TorreAmione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, et al. A highly immunogenic tumor transfected with a murine transforming growth factor type β 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87:1486-90.
71. Stander M, Naumann U, Dumitrescu L, Heneka M, Loschmann P, Gulbins E, et al. Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther 1998; 5:1187-94.
72. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001; 7:1118-22.
73. Shah AH, Tabayoyong WB, Kundu SD, Kim SJ, Van Parijs L, Liu VC, et al. Suppression of tumor metastasis by blockade of transforming growth factor β signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res 2002; 62:7135-8.
74. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3:666-75.
75. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells. Proc Natl Acad Sci USA 2004; 101:1969-74.
76. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, et al. Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: Dissection of Ras signaling pathways. J Cell Biol 2002; 156:299-313.
77. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002; 4:487-94.
78. Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M. Ets1 is an effector of the transforming growth factor β (TGF-β) signaling pathway and an antagonist of the profibrotic effects of TGF-β. J Biol Chem 2002; 277:20399-408.
79. Lindemann RK, Ballschmieter P, Nordheim A, Dittmer J. Transforming growth factor β regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism. J Biol Chem 2001; 276:46661-70.
80. Ha- induced changes in gene expression in neoplastic keratinocytes. Cancer Res 2000; 60:6332-8.
81. Risse-Hackl G, Adamkiewicz J, Wimmel A, Schuermann M. Transition from SCLC to NSCLC phenotype is accompanied by an increased TREbinding activity and recruitment of specific AP-1 proteins. Oncogene 1998; 16:3057-68.
82. Qing J, Zhang Y, Derynck R. Structural and functional characterization of the transforming growth factor-β-induced Smad3/c-Jun transcriptional cooperativity. J Biol Chem 2000; 275:38802-12.
83. Verrecchia F, Vindevoghel L, Lechleider RJ, Uitto J, Roberts AB, Mauviel A. Smad3/AP-1 interactions control transcriptional responses to TGF-β in a promoter-specific manner. Oncogene 2001; 20:3332-40.
84. Verrecchia F, Pessah M, Atfi A, Mauviel A. Tumor necrosis factor-α inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000; 275:30226-31.
85. Prunier C, Mazars A, Noe V, Bruyneel E, Mareel M, Gespach C, et al. Evidence that Smad2 is a tumor suppressor implicated in the control of cellular invasion. J Biol Chem 1999; 274:22919-22.
86. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-β. Proc Natl Acad Sci USA 2001; 98:6686-91.
87. Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, et al. Functional characterization of transforming growth factor β signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem 2001; 276:19945-53.
88. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62:65-74.
89. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, et al. Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5). J Med Chem 2002; 45:999-1001.
90. Vijayachandra K, Lee J, Glick AB. Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model. Cancer Res 2003; 63:3447-52.
91. Blessing M, Nanney LB, King LE, Hogan BL. Chemical skin carcinogenesis is prevented in mice by the induced expression of a TGF-β related transgene. Teratog Carcinog Mutagen 1995; 15:11-21.
92. Pierce DF, Gorska AE, Chytil A, Meise KS, Page DL, Coffey Jr RJ, et al. Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc Natl Acad Sci USA 1995; 92:4254-8.